Carisma Therapeutics Files 8-K
Ticker: CARM · Form: 8-K · Filed: Apr 10, 2024 · CIK: 1485003
Sentiment: neutral
Topics: 8-K, corporate-filing, pharmaceuticals
TL;DR
Carisma Therapeutics filed an 8-K on 4/10/24. Standard reporting.
AI Summary
Carisma Therapeutics Inc. filed an 8-K on April 10, 2024, reporting other events and financial statements. The company, formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc., is incorporated in Delaware and based in Philadelphia, PA.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for other events and financial statements, not indicating any immediate material changes or risks.
Key Numbers
- 001-36296 — SEC File Number (Identifies the company's filing with the SEC)
- 26-2025616 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Carisma Therapeutics Inc. (company) — Registrant
- Sesen Bio, Inc. (company) — Former company name
- Eleven Biotherapeutics, Inc. (company) — Former company name
- April 10, 2024 (date) — Date of earliest event reported
- 3675 Market Street, Suite 200, Philadelphia, PA 19104 (address) — Company's business and mail address
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond stating that this item is included in the filing.
What is the significance of the former company names 'Sesen Bio, Inc.' and 'Eleven Biotherapeutics, Inc.'?
These are former names of Carisma Therapeutics Inc., indicating a history of name changes or mergers.
What is the primary business of Carisma Therapeutics Inc. based on its SIC code?
The Standard Industrial Classification (SIC) code 2834 indicates the company is in the 'Pharmaceutical Preparations' industry.
When was Carisma Therapeutics Inc. incorporated and what is its fiscal year end?
The company is incorporated in Delaware, and its fiscal year ends on December 31st.
What is the physical address and phone number of Carisma Therapeutics Inc.?
The company's business and mail address is 3675 Market Street, Suite 200, Philadelphia, PA 19104, and its business phone number is 2674916422.
Filing Stats: 748 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-04-10 08:00:33
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CARM The Nasdaq Stock Mar
Filing Documents
- tm2411506d1_8k.htm (8-K) — 28KB
- tm2411506d1_ex99-1.htm (EX-99.1) — 12KB
- tm2411506d1_ex99-1img001.jpg (GRAPHIC) — 423KB
- tm2411506d1_ex99-1img002.jpg (GRAPHIC) — 301KB
- tm2411506d1_ex99-1img003.jpg (GRAPHIC) — 397KB
- tm2411506d1_ex99-1img004.jpg (GRAPHIC) — 434KB
- tm2411506d1_ex99-1img005.jpg (GRAPHIC) — 435KB
- tm2411506d1_ex99-1img006.jpg (GRAPHIC) — 422KB
- tm2411506d1_ex99-1img007.jpg (GRAPHIC) — 428KB
- tm2411506d1_ex99-1img008.jpg (GRAPHIC) — 237KB
- tm2411506d1_ex99-1img009.jpg (GRAPHIC) — 233KB
- 0001104659-24-045577.txt ( ) — 4776KB
- carm-20240410.xsd (EX-101.SCH) — 3KB
- carm-20240410_lab.xml (EX-101.LAB) — 33KB
- carm-20240410_pre.xml (EX-101.PRE) — 22KB
- tm2411506d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On April 10, 2024, during presentations at the American Association for Cancer Research 2024 Annual Meeting and the Annual Needham Virtual Healthcare Conference, Carisma Therapeutics Inc. (the "Company") will provide preliminary data from the Company's Phase 1 clinical trial of its first product candidate, CT-0508, a human epidermal growth factor receptor 2 ("HER2") targeted chimeric antigen receptor macrophage for the treatment of HER2 overexpressing cancers, as well as preliminary data from the first three patients treated in the Company's sub-study utilizing CT-0508 in combination with pembrolizumab. An excerpt from the presentation is attached hereto as 99.1 and is incorporated herein by reference. The Company is providing the following data: Based on preliminary results assessed to date from the 14 patients enrolled in group 1 and group 2 of the Company's monotherapy treatment clinical trial, 40.7% of all target lesions had reduced in size on at least one scan across all anatomic sites. The Company has enrolled six patients in its sub-study utilizing CT-0508 in combination with pembrolizumab. Based on preliminary results assessed to date from the first three patients treated in the sub-study, whose demographics are consistent with the 14 patients enrolled in group 1 and group 2 of the monotherapy clinical trial, the combination therapy has been generally well-tolerated after infusion with no dose-limiting toxicities. The first two of theinitial three patients enrolled in the combination study were treated with corticosteroids after receiving a CT-0508 infusion and prior to pembrolizumab administration. The Company believes that systemic corticosteroids have the potential to reverse the activity of CT-0508. Based on in vitro studies, corticosteroids lead to CT-0508 cell death. The Company observed a best overall response of progressive disease in the first two patients and stable disease in the third patient per RECIST 1.1 criteria.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Excerpt from Company Presentation, dated April 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARISMA THERAPEUTICS INC. By: /s/ Steven Kelly Date: April 10 , 2024 Steven Kelly President and Chief Executive Officer